TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced that it has completed an agreement with the Centre for
Popularity: unranked [?]
Related posts:
- CeNeRx BioPharma Announces Successful Completion Of Phase L Clinical Program For Novel Antidepressant Agent Tyrima(TM)
- CeNeRx BioPharma Announces Successful Completion Of Phase L Clinical Program For Novel Antidepressant Agent Tyrima(TM)
- CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
- CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
- CeNeRx BioPharma Initiates Human Trials Of RIMA Antidepressant
Comments
No Responses to “TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy”